Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues

British Journal of Pharmacology

Volumn 155, Issue 4, 2008, Pages 585-595

  Waldhauser, K M ^a   Brecht, K ^a   Hebeisen, S ^b   Ha, H R ^c   Konrad, D ^b   Bur, D ^d   Krahenbuhl S ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Bsys Ltd   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Amiodarone; Class III antiarrhythmics; Hepatic toxicity; hERG channel; Pulmonary toxicity

Indexed keywords

AMIODARONE; AMIODARONE DERIVATIVE; BENZOFURAN DERIVATIVE; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; CHANNEL GATING; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER TOXICITY; LUNG TOXICITY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CELL LINE, TUMOR; ETHER-A-GO-GO POTASSIUM CHANNELS; HEPATOCYTES; HUMANS; LUNG; MEMBRANE POTENTIAL, MITOCHONDRIAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53849095113     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.287     Document Type: Article

References (44)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl 2): S1-S209.
2. Bigler L, Spirli C, Fiorotto R, Pettenazzo A, Duner E, Baritussio A et al. (2007). Synthesis and cytotoxicity properties of amiodarone analogues. Eur J Med Chem 42: 861-867.
3. Bolt MW, Card JW, Racz WJ, Brien JF, Massey TE (2001a). Disruption of mitochondrial function and cellular ATP levels by amiodarone and N-desethylamiodarone in initiation of amiodarone-induced pulmonary cytotoxicity. J Pharmacol Exp Ther 298: 1280-1289.
4. Bolt MW, Racz WJ, Brien JF, Massey TE (2001b). Effects of vitamin E on cytotoxicity of amiodarone and N-desethylamiodarone in isolated hamster lung cells. Toxicology 166: 109-118.
5. Braumann T (1986a). Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships. J Chromatogr 373: 191-225.
6. Braumann T (1986b). Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships. J Chromatogr 373: 191-225.
7. Card JW, Lalonde BR, Rafeiro E, Tam AS, Racz WJ, Brien JF et al. (1998). Amiodarone-induced disruption of hamster lung and liver mitochondrial function: lack of association with thiobarbituric acid-reactive substance production. Toxicol Lett 98: 41-50.
8. Card JW, Racz WJ, Brien JF, Massey TE (2003). Attenuation of amiodarone-induced pulmonary fibrosis by vitamin E is associated with suppression of transforming growth factor-beta1 gene expression but not prevention of mitochondrial dysfunction. J Pharmacol Exp Ther 304: 277-283.
9. Chatelain P, Meysmans L, Matteazzi JR, Beaufort P, Clinet M (1995). Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol 116: 1949-1956.
10. 2+ channel current in Xenopus oocytes by amiodarone. J Investig Med 49: 346-352.
11. + conduction and selectivity. Science 280: 69-77.
12. Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y (1993). Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 21: 978-985.
13. Flanagan RJ, Storey GC, Holt DW, Farmer PB (1982). Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients. J Pharm Pharmacol 34: 638-643.
14. Fromenty B, Fisch C, Berson A, Letteron P, Larrey D, Pessayre D (1990a). Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 255: 1377-1384.
15. Fromenty B, Fisch C, Labbe G, Degott C, Deschamps D, Berson A et al. (1990b). Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 255: 1371-1376.
16. Gerber PR (1998). Charge distribution from a simple molecular orbital type calculation and non-bonding interaction terms in the force field MAB. J Comput Aided Mol Des 12: 37-51.
17. Ha HR, Bigler L, Wendt B, Maggiorini M, Follath F (2005). Identification and quantitation of novel metabolites of amiodarone in plasma of treated patients. Eur J Pharm Sci 24: 271-279.
18. Ha HR, Candinas R, Stieger B, Meyer UA, Follath F (1996). Interaction between amiodarone and lidocaine. J Cardiovasc Pharmacol 28: 533-539.
19. Ha HR, Stieger B, Grassi G, Altorfer HR, Follath F (2000). Structure-effect relationships of amiodarone analogues on the inhibition of thyroxine deiodination. Eur J Clin Pharmacol 55: 807-814.
20. Harjai KJ, Licata AA (1997). Effects of amiodarone on thyroid function. Ann Intern Med 126: 63-73.
21. Hostetler KY, Giordano JR, Jellison EJ (1988). In vitro inhibition of lysosomal phospholipase A1 of rat lung by amiodarone and desethylamiodarone. Biochim Biophys Acta 959: 316-321.
22. Hostetler KY, Reasor MJ, Walker ER, Yazaki PJ, Frazee BW (1986). Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats. Biochim Biophys Acta 875: 400-405.
23. Jessurun GA, Boersma WG, Crijns HJ (1998). Amiodarone-induced pulmonary toxicity. Predisposing factors, clinical symptoms and treatment. Drug Saf 18: 339-344.
24. Kaufmann AM, Krise JP (2007). Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci 96: 729-746.
25. Kaufmann P, Torok M, Hanni A, Roberts P, Gasser R, Krahenbuhl S (2005). Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 41: 925-935.
26. Kaufmann P, Torok M, Zahno A, Waldhauser KM, Brecht K, Krahenbuhl S (2006). Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 63: 2415-2425.
27. Krahenbuhl S, Brandner S, Kleinle S, Liechti S, Straumann D (2000). Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 20: 346-348.
28. Lalevee N, Nargeot J, Barrere-Lemaire S, Gautier P, Richard S (2003). Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol 14: 885-890.
29. Lewis JH, Mullick F, Ishak KG, Ranard RC, Ragsdale B, Perse RM et al. (1990). Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 21: 59-67.
30. Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG et al. (1989). Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 9: 679-685.
31. Lullmann H, Lullmann-Rauch R, Wassermann O (1975). Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Rev Toxicol 4: 185-218.
32. Martin II WJ, Rosenow III EC (1988a). Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest 93: 1242-1248.
33. Martin II WJ, Rosenow III EC (1988b). Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest 93: 1067-1075.
34. Mason JW (1987). Amiodarone. N Engl J Med 316: 455-466.
35. + selectivity filter. Nature 414: 37-42.
36. Morse RM, Valenzuela GA, Greenwald TP, Eulie PJ, Wesley RC, McCallum RW (1988). Amiodarone-induced liver toxicity. Ann Intern Med 109: 838-840.
37. O'Brien J, Wilson I, Orton T, Pognan F (2000). Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267: 5421-5426.
38. Pitcher WD (1992). Amiodarone pulmonary toxicity. Am J Med Sci 303: 206-212.
39. Pollak PT (1999). Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol 84: 37R-45R.
40. Singh BN (1996). Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol 78: 41-53.
41. Spaniol M, Bracher R, Ha HR, Follath F, Krahenbuhl S (2001). Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J Hepatol 35: 628-636.
42. Waldhauser KM, Torok M, Ha HR, Thomet U, Konrad D, Brecht K et al. (2006). Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J Pharmacol Exp Ther 319: 1413-1423.
43. Yasuda SU, Sausville EA, Hutchins JB, Kennedy T, Woosley RL (1996). Amiodarone-induced lymphocyte toxicity and mitochondrial function. J Cardiovasc Pharmacol 28: 94-100.
44. + channel-Fab complex at 2.0 Å resolution. Nature 414: 43-48.